Literature DB >> 11026102

Mucoepidermoid carcinoma involving Warthin tumor. A report of five cases and review of the literature.

J D Williamson1, B H Simmons, A el-Naggar, L J Medeiros.   

Abstract

We describe 5 cases of mucoepidermoid carcinoma (MEC) involving Warthin tumor (WT) of the parotid gland. The WT size ranged from 1.7 to 6.0 cm. The MECs were much smaller, 0.3 to 1.7 cm. In 3 cases, the WT completely surrounded the MEC, and in 2 cases neither WT nor MEC surrounded the other. Each MEC was low grade, 3 grade I and 2 grade II. One MEC had evidence of vascular invasion. All patients underwent partial or subtotal parotidectomy with negative resection margins. Clinical follow-up (range, 8-52 months) for 3 patients showed no evidence of recurrence. The pathogenetic relationship between WT and MEC in these cases is uncertain. In 4 cases, foci of squamous or mucous metaplasia were found in the WT component, associated with mild cytologic atypia in 3 tumors. However, a direct transition from WT to MEC was not identified. In 1 case, MEC was present 45 months before WT, suggesting that the recurrent MEC involved WT coincidentally. The small size and low grade of the MEC and the negative resection margins most likely explain the good outcome for the 3 patients with clinical follow-up data available.

Entities:  

Mesh:

Year:  2000        PMID: 11026102     DOI: 10.1309/GUT1-F58A-V4WV-0D8P

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  11 in total

1.  Prevalence of Lymphoid Neoplasia in a Retrospective Analysis of Warthin Tumor: A Single Institution Experience.

Authors:  F N U Alnoor; Jatin S Gandhi; Matthew K Stein; Jorge Solares; Joel F Gradowski
Journal:  Head Neck Pathol       Date:  2020-04-23

2.  The MECT1-MAML2 gene fusion and benign Warthin's tumor: is the MECT1-MAML2 gene fusion specific to mucuepidermoid carcinoma?

Authors:  Marta Winnes; Fredrik Enlund; Joachim Mark; Göran Stenman
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

3.  MAML2 Rearrangements in Variant Forms of Mucoepidermoid Carcinoma: Ancillary Diagnostic Testing for the Ciliated and Warthin-like Variants.

Authors:  Justin A Bishop; Morgan L Cowan; Chung H Shum; William H Westra
Journal:  Am J Surg Pathol       Date:  2018-01       Impact factor: 6.394

Review 4.  Diagnostic Approach to Fine Needle Aspirations of Cystic Lesions of the Salivary Gland.

Authors:  Liron Pantanowitz; Lester D R Thompson; Esther Diana Rossi
Journal:  Head Neck Pathol       Date:  2018-03-09

5.  Squamous carcinoma arising in a parotid Warthin's tumour.

Authors:  Fabiana Allevi; Federico Biglioli
Journal:  BMJ Case Rep       Date:  2014-12-12

6.  A study of MECT1-MAML2 in mucoepidermoid carcinoma and Warthin's tumor of salivary glands.

Authors:  Carmo Martins; Branca Cavaco; Giovanni Tonon; Frederic J Kaye; Jorge Soares; Isabel Fonseca
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

Review 7.  Primary Intraosseous Mucoepidermoid Carcinoma of the Maxilla.

Authors:  S M Nallamilli; R Tatapudi; R S Reddy; M Ravikanth; N Rajesh
Journal:  Ghana Med J       Date:  2015-06

8.  Mucoepidermoid carcinoma in Warthin tumor of the parotid gland.

Authors:  Wojciech Smółka; Jarosław Markowski; Agnieszka Piotrowska-Seweryn; Piotr Paleń; Zuzanna Dobrosz; Włodzimierz Dziubdziela
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

9.  Warthin-like mucoepidermoid carcinoma of the parotid gland: a diagnostic and therapeutic dilemma.

Authors:  Vigneshwaran Balasubiramaniyan; Mahesh Sultania; Mukund Sable; Dillip Muduly; Madhabananda Kar
Journal:  Autops Case Rep       Date:  2019-09-30

10.  Poorly differentiated carcinoma arising from adenolymphoma of the parotid gland.

Authors:  Stefano Ferrero; Laura Cattaneo; Andrea Peri; Paola Braidotti; Ugo Cioffi; Gabriele Scaramellini; Michele M Ciulla; Matilde De Simone; Carmelo Arizzi; Lorenzo Pignataro
Journal:  BMC Surg       Date:  2003-01-17       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.